-+ 0.00%
-+ 0.00%
-+ 0.00%

Tivic Says Second, Follow-Up Meeting With BARDA Scheduled For March 10, To Continue Discussions On Clinical Data And Potential For Funding And Stockpiling Entolimod For ARS

Benzinga·02/18/2026 14:18:46
Listen to the news

Initial presentation on January 26, 2026 showcased Entolimod's potential to mitigate and prevent both gastrointestinal and hematopoietic injury from ionizing radiation exposure.

FREMONT, CA / ACCESS Newswire / February 18, 2026 / Tivic (NASDAQ:TIVC), a late-stage immuno-therapeutics company, today announced that a second, follow-up meeting with the Biomedical Advanced Research and Development Authority (BARDA) has been scheduled for March 10, 2026, to continue discussions focused on clinical data and the potential for funding and, ultimately, stockpiling Entolimod™ for Acute Radiation Syndrome (ARS).